FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022061861> ?p ?o ?g. }

• W3022061861 endingPage "76" @default.
• W3022061861 startingPage "67" @default.
• W3022061861 abstract "Renal cell carcinoma has the highest incidence rate of cancer types in the urinary system. Moreover, microRNAs (miRNA) have been closely associated with numerous types of tumor. The present study aimed to investigate the effects of miRNA (miR)‑133b on the proliferation, invasion and chemosensitivity of renal cell carcinoma cells, and to determine whether its mechanism was regulated by the ERK signaling pathway. Both renal cell carcinoma and adjacent healthy tissues from 60 patients, in addition to renal cell carcinoma lines, ACHN, Caki‑1, A‑498 and 786‑O, and 293 cells, were used in this study. miR‑133b expression was measured from renal cell carcinoma, adjacent healthy tissues and renal cell carcinoma cell lines by reverse transcription‑quantitative PCR. Cells were transfected with miR‑133b mimic to achieve miR‑133b overexpression. The proliferative, migratory and invasive ability of the cells were evaluated using MTT, wound healing and Matrigel assays, respectively, and flow cytometry was used to detect the apoptotic rate. Following treatment with an ERK inhibitor, U0126, and activator, LM22B‑10, western blotting was used to detect the expression of related proteins and the activity of the ERK signaling pathway. The overexpression of miR‑133b significantly inhibited cell proliferation, migration and invasion, whilst inducing apoptosis and increasing the drug sensitivity of renal cell carcinoma cells to cisplatin, docetaxel and doxorubicin. The miR‑133b mimic also increased the protein expression levels of Bax and decreased the expression levels of matrix metalloproteinase (MMP)‑2, MMP‑9, ATP‑binding cassette subfamily G2, P‑glycoprotein, Bcl‑2 and proliferating cell nuclear antigen, as well as the phosphorylation of ERK (P<0.05). The administration of the U0216 inhibitor demonstrated similar effects to miR‑133b overexpression, and there was no significant difference compared with the miR‑133b mimic transfection (P>0.05). However, the overexpression of miR‑133b combined with LM22B‑10 treatment weakened the anticancer effects of miR‑133b mimic transfection (P<0.05). In conclusion, miR‑133b overexpression was observed to inhibit the proliferation, migration and invasion of renal cell carcinoma cells and improve chemotherapeutic sensitivity; it was suggested that the mechanism maybe related to the inhibition of ERK1/2 phosphorylation and thus decreased ERK signaling pathway activity." @default.
• W3022061861 created "2020-05-13" @default.
• W3022061861 creator A5024074443 @default.
• W3022061861 creator A5031455736 @default.
• W3022061861 creator A5037414724 @default.
• W3022061861 creator A5055936299 @default.
• W3022061861 date "2020-05-05" @default.
• W3022061861 modified "2023-10-02" @default.
• W3022061861 title "miR‑133b affects cell proliferation, invasion and chemosensitivity in renal cell carcinoma by inhibiting the ERK signaling pathway" @default.
• W3022061861 cites W1041672667 @default.
• W3022061861 cites W144423133 @default.
• W3022061861 cites W1550210631 @default.
• W3022061861 cites W1992272392 @default.
• W3022061861 cites W2007251815 @default.
• W3022061861 cites W2014946489 @default.
• W3022061861 cites W2055380229 @default.
• W3022061861 cites W2063789527 @default.
• W3022061861 cites W2107277218 @default.
• W3022061861 cites W2111306860 @default.
• W3022061861 cites W2122033693 @default.
• W3022061861 cites W2264436887 @default.
• W3022061861 cites W2337672324 @default.
• W3022061861 cites W2511851068 @default.
• W3022061861 cites W2625018508 @default.
• W3022061861 cites W2732780281 @default.
• W3022061861 cites W2742677820 @default.
• W3022061861 cites W2769579100 @default.
• W3022061861 cites W2781525129 @default.
• W3022061861 cites W2887083804 @default.
• W3022061861 cites W2901427501 @default.
• W3022061861 cites W2908078217 @default.
• W3022061861 cites W2982385832 @default.
• W3022061861 cites W944533292 @default.
• W3022061861 doi "https://doi.org/10.3892/mmr.2020.11125" @default.
• W3022061861 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7248518" @default.
• W3022061861 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32377748" @default.
• W3022061861 hasPublicationYear "2020" @default.
• W3022061861 type Work @default.
• W3022061861 sameAs 3022061861 @default.
• W3022061861 citedByCount "10" @default.
• W3022061861 countsByYear W30220618612020 @default.
• W3022061861 countsByYear W30220618612021 @default.
• W3022061861 countsByYear W30220618612022 @default.
• W3022061861 countsByYear W30220618612023 @default.
• W3022061861 crossrefType "journal-article" @default.
• W3022061861 hasAuthorship W3022061861A5024074443 @default.
• W3022061861 hasAuthorship W3022061861A5031455736 @default.
• W3022061861 hasAuthorship W3022061861A5037414724 @default.
• W3022061861 hasAuthorship W3022061861A5055936299 @default.
• W3022061861 hasBestOaLocation W30220618611 @default.
• W3022061861 hasConcept C1491633281 @default.
• W3022061861 hasConcept C190283241 @default.
• W3022061861 hasConcept C2778608917 @default.
• W3022061861 hasConcept C2780394083 @default.
• W3022061861 hasConcept C2781018059 @default.
• W3022061861 hasConcept C29537977 @default.
• W3022061861 hasConcept C47170353 @default.
• W3022061861 hasConcept C502942594 @default.
• W3022061861 hasConcept C54355233 @default.
• W3022061861 hasConcept C55493867 @default.
• W3022061861 hasConcept C57074206 @default.
• W3022061861 hasConcept C62112901 @default.
• W3022061861 hasConcept C62478195 @default.
• W3022061861 hasConcept C81885089 @default.
• W3022061861 hasConcept C86803240 @default.
• W3022061861 hasConcept C95444343 @default.
• W3022061861 hasConceptScore W3022061861C1491633281 @default.
• W3022061861 hasConceptScore W3022061861C190283241 @default.
• W3022061861 hasConceptScore W3022061861C2778608917 @default.
• W3022061861 hasConceptScore W3022061861C2780394083 @default.
• W3022061861 hasConceptScore W3022061861C2781018059 @default.
• W3022061861 hasConceptScore W3022061861C29537977 @default.
• W3022061861 hasConceptScore W3022061861C47170353 @default.
• W3022061861 hasConceptScore W3022061861C502942594 @default.
• W3022061861 hasConceptScore W3022061861C54355233 @default.
• W3022061861 hasConceptScore W3022061861C55493867 @default.
• W3022061861 hasConceptScore W3022061861C57074206 @default.
• W3022061861 hasConceptScore W3022061861C62112901 @default.
• W3022061861 hasConceptScore W3022061861C62478195 @default.
• W3022061861 hasConceptScore W3022061861C81885089 @default.
• W3022061861 hasConceptScore W3022061861C86803240 @default.
• W3022061861 hasConceptScore W3022061861C95444343 @default.
• W3022061861 hasIssue "1" @default.
• W3022061861 hasLocation W30220618611 @default.
• W3022061861 hasLocation W30220618612 @default.
• W3022061861 hasLocation W30220618613 @default.
• W3022061861 hasOpenAccess W3022061861 @default.
• W3022061861 hasPrimaryLocation W30220618611 @default.
• W3022061861 hasRelatedWork W1981145072 @default.
• W3022061861 hasRelatedWork W2159406762 @default.
• W3022061861 hasRelatedWork W2348417465 @default.
• W3022061861 hasRelatedWork W2600552753 @default.
• W3022061861 hasRelatedWork W2620164270 @default.
• W3022061861 hasRelatedWork W2808352915 @default.
• W3022061861 hasRelatedWork W2907903807 @default.
• W3022061861 hasRelatedWork W2977485281 @default.
• W3022061861 hasRelatedWork W3092962564 @default.
• W3022061861 hasRelatedWork W3209843007 @default.

• next